• 1
    Lesser B, Bruchovsky N. The effects of 5α-dihydrotestosterone on the kinetics of cell proliferation in rat prostate. Biochem J. 1974; 142: 483489.
  • 2
    Lesser B, Bruchovsky N. Effect of duration of the period after castration on the response of the rat ventral prostate to androgens. Biochem J. 1974; 142: 429431.
  • 3
    Lesser B, Bruchovsky N. The effects of testosterone, 5α-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta. 1973; 308: 42637.
  • 4
    Bruchovsky N, Lesser B, Van Doorn E, Craven S. Hormonal effects on cell proliferation in rat prostate. Vitam Horm. 1975; 33: 61102.
  • 5
    Foulds L. Neoplastic development, vol 1. New York: Academic Press, 1969; 73.
  • 6
    Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res. 1977; 37: 8294.
  • 7
    Bruchovsky N, Rennie PS, Van Doorn E, Noble RL. Pathological growth of androgen-sensitive tissues resulting from latent actions of steroid hormones. J Toxicol Environ Health. 1978; 4: 391408.
  • 8
    Bruchovsky N, Goldie JH. Basis for the use of drug and hormone combinations in the treatment of endocrine-related cancer. In: BruchovskyN, GoldieJH, editors. Drug and hormone resistance in neoplasia, vol II, clinical concepts. Boca Raton: CRC Press, 1983: 129162.
  • 9
    Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993; 71: 27822790.
  • 10
    Minesita T, Yamaguchi K. An androgen-dependent tumor derived from a hormone-independent spontaneous tumor of a female mouse. Steroids. 1964; 4: 815829.
  • 11
    Bruchovsky N, Sutherland DJA, Meakin JW, Minesita T. Androgen receptors: relationship to growth response and to intracellular androgen transport in nine variant lines of the Shionogi mouse mammary carcinoma. Biochim Biophys Acta. 1975; 381: 6171.
  • 12
    Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990; 50: 22752282.
  • 13
    Akakura K, Bruchovsky N, Rennie PS, et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (Clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol. 1996; 59: 501511.
  • 14
    Klotz LH, Herr HW, Morse MJ, Whitmore WFJr. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986; 58: 25462550.
  • 15
    Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995; 45: 839844.
  • 16
    Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996; 48: 800804.
  • 17
    Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol. 1996; 30( Suppl 1): 2225.
  • 18
    Oliver RTD, Williams G, Paris AMI, Blandy JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology. 1997; 49: 7982.
  • 19
    Theyer G, Holub S, Durer A, et al. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer. 1997; 75: 15151518.
  • 20
    Grossfeld CD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998; 51: 137144.
  • 21
    Horwich A, Huddart RA, Gadd J, et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol. 1998; 81: 9699.
  • 22
    Bruchovsky N, Goldenberg L, Gleave M. Intermittent androgen suppression for the treatment of prostate cancer. In: BelldegrunA, KirbyRS, OliverRTD, editors. New perspectives in prostate cancer. Oxford: Isis Medical Media, 1998: 273282.
  • 23
    Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology. 1999; 53: 530534.
  • 24
    Bruchovsky N, Klotz LH, Sadar MD, et al. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol. 2000; 4: 191201.
  • 25
    Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist. 2000; 5: 4552.
  • 26
    Bouchot O, Lenormand L, Karam G, et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol. 2000; 38: 543549.
  • 27
    Prapotnich D, Fizazi K, Escudier B. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol. 2003; 43: 233239.
  • 28
    Albrecht W, Collette L, Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol. 2003; 44: 505511.
  • 29
    De La Taille A, Zerbib M, Conquy S, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int. 2003; 91: 1822.
  • 30
    Lane TM, Ansell W, Farrugia D, et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int. 2004; 73: 117122.
  • 31
    Bruchovsky N, Theyer G. Second international workshop on intermittent androgen ablation therapy, meeting report. Eur Urol Today. 2000; 11: 45.
  • 32
    de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002; 1: 163171.
  • 33
    Calais da Silva F, Bono A, Whelan P, et al. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group. Oncology. 2003; 65( Suppl 1): 2428.
  • 34
    Pether M, Goldenberg SL. Intermittent androgen suppression. BJU Int. 2004; 93: 258261.
  • 35
    Sato N, Akakura K, Isaka S, et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology. 2004; 64: 341345.
  • 36
    Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991; 145: 984987.
  • 37
    Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer. 1999; 6: 487502.
  • 38
    Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996; 58: 139146.